Early Access — free while we kick the tires
EdgarHawk

VAN NOSTRAND ROBERT L

Director

Director
2 filings analyzed · 2 companies · Latest 2025-06-13

Companies

Company Buys Sells Direction
SELLAS Life Sciences Group, Inc. SLS 1 0 Net buying
Intra-Cellular Therapies, Inc. ITCI 0 3 Net selling

Activity

June 2025
Buy
10,000 shares
$14,800
Significance 4/10

Director Robert L Van Nostrand buys 10,000 shares of SLS at $1.48; holdings double to 20.4K shares.

Director Robert L Van Nostrand purchased 10,000 shares at $1.48 on 2025-06-12, doubling his shareholding from 10,400 to 20,400 shares. The company reports $0.00 revenue in the latest quarter and net income of $-5,813,000.00, with annual revenue declining 100.0% year-over-year, indicating severe operational stress. While the stock has appreciated +9.9% over the past 30 days and +45.6% over 90 days from depressed levels, the director's open-market track record across all securities shows mixed results—his prior sells (4 total) averaged -3.2% returns over 30 days and -5.5% over 90 days, with 100.00% of those sales well-timed relative to subsequent stock declines. The purchase at $1.48 occurs $0.18 below current price of $1.66, within the 52-week range of $0.84–$1.94. This transaction represents a substantial increase in director exposure to a pre-revenue company in distress, warranting examination of whether operational recovery plans or capital allocation changes underpin the move.

June 2024
Sell
20,000 shares
$1,518,199
Significance 6/10

Director Van Nostrand sold 20,000 shares (20.0K shares) for $1,518,199.24 at ITCI, reducing holdings by -67.4%

Director Robert L Van Nostrand executed two separate sales on 2024-06-18, selling 8,891 shares at $75.71 and 11,109 shares at $76.07, totaling 20,000 shares (20.0K shares) for $1,518,199.24 and reducing his holdings from 29,690 to 9,690 shares (a -67.4% reduction). His prior two sells at ITCI on 2024-02-27 were both well-timed at the 90-day mark, showing a consistent pattern of selling before declines. The company currently trades at $76.58 near its 52-week high of $79.84, while facing unprofitability ($-15,247,000 net income in the latest quarter) despite strong revenue growth of +85.5% year-over-year. The substantial disposition of two-thirds of his holdings by a director, combined with his historical pattern of well-timed sells at this ticker and the stock's proximity to 52-week highs amid ongoing losses, represents a material signal warranting close monitoring of company performance and insider sentiment.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access